title: Use of transfer factor for the treatment of recurrent non-bacterial female cystitis (NBRC): a preliminary report.
abstract: Results of conventional treatment of female non-bacterial recurrent cystitis (NBRC) are discouraging. Most patients show an unexpected high incidence of vaginal candidiasis, while their cell mediated immunity to Herpes simplex viruses (HSV) and Candida antigens seems impaired, and it is known that the persistence of mucocutaneous chronic candidiasis is mainly due to a selective defect of CMI to Candida antigens. Twenty nine women suffering of NBRC, and in whom previous treatment with antibiotics and non-steroid anti-inflammatory drugs was unsuccessful, underwent oral transfer factor (TF) therapy. TF specific to Candida and/or to HSV was administered bi-weekly for the first 2 weeks, and then once a week for the following 6 months. No side effects were observed during treatment. The total observation period of our cohort was 24379 days with 353 episodes of cystitis recorded and a cumulative relapse index (RI) of 43. The observation period during and after treatment was 13920 days with 108 relapses and a cumulative RI of 23 (P < 0.0001). It, thus, seems that specific TF may be capable of controlling NBRC and alleviate the symptoms.
authors.affiliation: Immunodiagnosis and Immunotherapy Unit, 1st-Division of Urology, Bologna, Italy.
authors.forename: C
authors.initials: C
authors.lastname: De Vinci
authors.forename: G
authors.initials: G
authors.lastname: Pizza
authors.forename: D
authors.initials: D
authors.lastname: Cuzzocrea
authors.forename: D
authors.initials: D
authors.lastname: Menniti
authors.forename: E
authors.initials: E
authors.lastname: Aiello
authors.forename: P
authors.initials: P
authors.lastname: Maver
authors.forename: G
authors.initials: G
authors.lastname: Corrado
authors.forename: P
authors.initials: P
authors.lastname: Romagnoli
authors.forename: E
authors.initials: E
authors.lastname: Dragoni
authors.forename: G
authors.initials: G
authors.lastname: LoConte
authors.forename: U
authors.initials: U
authors.lastname: Riolo
authors.forename: M
authors.initials: M
authors.lastname: Masi
authors.forename: G
authors.initials: G
authors.lastname: Severini
authors.forename: V
authors.initials: V
authors.lastname: Fornarola
authors.forename: D
authors.initials: D
authors.lastname: Viza
mesh_terms: D000328:Adult; D000368:Aged; D002176:Candida albicans / Q000276:immunology; D003556:Cystitis / Q000276:immunology* / Q000628:therapy*; D003587:Cytomegalovirus / Q000276:immunology; D005260:Female; D006558:Herpes Genitalis / Q000097:blood; D006561:Herpes Simplex / Q000097:blood; D018259:Herpesvirus 1, Human / Q000276:immunology; D018258:Herpesvirus 2, Human / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D008875:Middle Aged; D012680:Sensitivity and Specificity; D014165:Transfer Factor / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D014165:Transfer Factor